Benedict Kaitlin, Jordan Alexander, Gold Jeremy A W, Smith Dallas J, Chiller Tom, Hennessee Ian, Polgreen Philip M, Beekmann Susan E
Emerg Infect Dis. 2025 Jul;31(7):1493-1495. doi: 10.3201/eid3107.250295.
We polled infectious disease specialists about cryptococcal antigen screening for patients initiating HIV antiretroviral therapy. Of 215 respondents, 33% reported typically obtaining screening for patients with CD4 counts <200 cells/mm and 63% for counts <100 CD4 cells/mm. Uncertainty about cryptococcal antigen screening benefits and recommendations suggests opportunities for education and increased screening.
我们就开始接受人类免疫缺陷病毒（HIV）抗逆转录病毒治疗的患者进行隐球菌抗原筛查一事，对传染病专家进行了调查。在215名受访者中，33%报告称通常会对CD4细胞计数低于200个/立方毫米的患者进行筛查，63%的受访者会对CD4细胞计数低于100个/立方毫米的患者进行筛查。对于隐球菌抗原筛查的益处和建议存在不确定性，这表明有开展教育和增加筛查的机会。
